FDA Weighs Peptide Decision; Merck Ebola Vaccine Shows Promise in DRC Outbreak

The FDA is weighing a politically charged decision on compounded peptides amid an ongoing regulatory dispute. Revolution Medicines is advancing a promising pancreatic cancer drug toward approval. New evidence suggests that Merck's Ebola vaccine may help blunt the Bundibugyo strain outbreak currently affecting the Democratic Republic of Congo.